Abstract 175P
Background
Advanced gastric adenocarcinoma with both lymph node and peritoneal metastasis has notoriously poor prognosis. However, molecular mechanism of the metastatic process and potential therapeutic targets remain unknown, hence limiting the development of new therapies.
Methods
We recruited 13 treatment-naïve patients who had gastric adenocarcinoma with concurrent lymph node and peritoneal metastasis. DNA and RNA were extracted from tumor biopsy samples collected from the stomach, lymph node and peritoneum, together with 2 mL of peripheral blood for each patient. Whole exome sequencing (WES) and transcriptome sequencing were performed to generate a comprehensive genomic dataset of our cohort.
Results
Analysis of WES data showed that TP53 and CDH1 were the most frequently mutated genes in both the primary and metastatic tumors. All patients had low tumor mutational burden, but 31% (n=4) showed high level of chromosomal instability (CIN). By constructing tumor phylogenetic trees for each patient, we found evidence supporting two distinct processes of peritoneal dissemination that involved either lymphatic system (n=5) or direct seeding into the peritoneal cavity (n=4). In the RNA sequencing analysis, epithelial-mesenchymal transition (EMT) pathway was found the most significantly altered and segregated the patients into the EMT-high group (n=10) that upregated genes in the EMT pathway, and the non-EMT-high group (n=3).
Conclusions
Multi-omics profiling in this study revealed mutational signature and altered signaling pathways in lymph node and peritoneal metastasis. The results could help identify distinct molecular subtypes among patients, laying foundation for the development of molecular-guided therapeutic strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Genetics Institute, Ho Chi Minh city, Vietna.
Funding
Gene Solutions JSC, Ho Chi Minh city, Vietnam.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract